LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Kodu・Aktsiate loetelu・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Suletud

SektorTervishoid

21.31 0.14

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.3

Max

21.31

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -21M
Müük	14M 54M
Kasumimarginaal	-39.611
Töötajad	178
EBITDA	-3.8M -23M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-2.11% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	1B 2.2B
Eelmine avamishind	21.17
Eelmine sulgemishind	21.31

Uudiste sentiment

By Acuity

50%

141 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

6.26 / 7.47 Toetus ja vastupanu

Day One Biopharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. märts 2026, 19:08 UTC

Uudisväärsed sündmused

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13. märts 2026, 18:48 UTC

Tulu

Suurimad hinnamuutused turgudel

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13. märts 2026, 16:47 UTC

Uudisväärsed sündmused

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

14. märts 2026, 15:00 UTC

Uudisväärsed sündmused

Iran War Delivers Windfall to America's Oil Country -- WSJ

14. märts 2026, 02:03 UTC

Tulu

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14. märts 2026, 01:32 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14. märts 2026, 00:29 UTC

Omandamised, ülevõtmised, äriostud

13D Filings -- Barrons.com

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13. märts 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

13. märts 2026, 18:49 UTC

Uudisväärsed sündmused

The Iran War Could Upend AI. Here's How. -- Barrons.com

13. märts 2026, 18:24 UTC

Uudisväärsed sündmused

Impact of Middle East Conflict on TotalEnergies Activities

13. märts 2026, 18:00 UTC

Uudisväärsed sündmused

Is War Good For the Economy? -- WSJ

13. märts 2026, 17:23 UTC

Market Talk

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13. märts 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13. märts 2026, 16:38 UTC

Uudisväärsed sündmused

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13. märts 2026, 16:34 UTC

Omandamised, ülevõtmised, äriostud

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13. märts 2026, 16:33 UTC

Omandamised, ülevõtmised, äriostud

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13. märts 2026, 16:32 UTC

Omandamised, ülevõtmised, äriostud

EQT Completes Exit From Galderma

13. märts 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Day One Biopharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

-2.11% langus

12 kuu keskmine prognoos

Keskmine 20.86 USD -2.11%

Kõrge 21.5 USD

Madal 17 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Day One Biopharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Day One Biopharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

6.26 / 7.47Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

141 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.